GW Pharmaceuticals boss: Cannabis-based treatments could be used in autism

By Denise Roland 1:17PM GMT 02 Dec 2014

Justin Gover says GW’s experimental drug for severe epilepsy also appears to treat symptoms of autism

GW Pharmaceuticals is to investigate whether a cannabis-based medicine could treat symptoms of severe autism.
The British drugmaker, which develops medicines using cannabis extracts, is putting together the “building blocks” of a research programme into autism, its chief executive told The Telegraph.
Justin Gover said doctors treating severely epileptic children with GW’s experimental drug Epidiolex had observed improvements in behaviour and brain function in those patients who also had autism.
He cautioned that the observations were “no more scientific at this stage” but that he saw an “important role for GW in researching the use of cannabinoids within autism-like disorders”.

http://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/11267891/GW-Pharmaceuticals-boss-Cannabis-based-treatments-could-be-used-in-autism.html